Phase Ib Study of the Combination of Pazopanib, an Oral VEGFR Inhibitor, and ARQ 197 (Tivantinib), an Oral MET Inhibitor, in Patients With Refractory Advanced Solid Tumors.
Phase of Trial: Phase I
Latest Information Update: 19 May 2017
At a glance
- Drugs Tivantinib (Primary) ; Pazopanib
- Indications Gastric cancer; Sarcoma; Solid tumours
- Focus Adverse reactions
- 07 Jun 2016 Results presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
- 12 Feb 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 18 Dec 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.